China Biotech Services Holdings Limited provided consolidated earnings guidance for the six months ended 30 June 2018. The group is expected to record a net loss of not less than HKD 26,000,000 for the 2018 interim period as compared to the net loss of approximately HKD 9,500,000 recorded for the corresponding period in 2017. The expected increase in net loss for the 2018 Interim Period was mainly attributable to amortisation of equity-settled share-based payment of approximately HKD 6,180,000 in relation to the granting of share options (as opposed to the absence of such amortisation for the corresponding period in 2017); increase in administrative expenses (excluding amortisation of equity-settled share-based payment) of approximately HKD 4,886,000; and neither a gain on disposal of associates and subsidiaries nor gain or loss on fair value change of financial assets at fair value through profit or loss would be recorded (as opposed to a gain on disposal of associates and subsidiaries of approximately HKD 28,031,000 being recorded which was partially offset by a net loss of approximately HKD 22,185,000 on financial assets at fair value through profit or loss for the corresponding period in 2017).